Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2007

View Archived Issues

Medivir completes enrollment of phase III program for topical Lipsovir

bioMerieux to develop companion test for Ipsen's BN-83495

Phosphagenics submits IND for transdermal oxycodone for chronic pain

Initial phase I results show IMO-2055 plus chemotherapy feasible for solid tumors

XL-647 demonstrates antitumor activity in non-small cell lung cancer patients

Recent data on triple angiokinase inhibitor BIBF-1120 in NSCLC presented

Retreatment with Tookad phototherapy feasible and active in prostate cancer

Preclinical data on potential targets for the development of agents for sleep disorders

Cannasat Therapeutics' pain therapy delivered with IntelGenx technology in phase I trial

Asubio Pharma acquires exclusive rights to Kuvan NDA data for filing in Japan

Pharmacopeia begins phase IIa study of PS-433540 for hypertension

Patient enrollment completed for Sciele Pharma's pivotal phase III trial of glycopyrrolate

Microbia and Forest to codevelop and comarket linaclotide for gastrointestinal disorders

Vasogen to begin 300-patient confirmatory study of Celacade technology

FDA allows IND exemption for Genta's tablet formulation of G-4544

Positive tesofensine results from NeuroSearch TIPO-1 study in obesity

Polydex reports final results from phase II trial of Ushercell for BV

Schering-Plough begins two phase III studies of CCR5 antagonist vicriviroc

Xenomics and Ipsogen sign licensing agreement for diagnostic assay for AML

Idera begins dosing patients in phase I trial of IMO-2125 for HCV

Novel agents for cancer treatment covered in recent patent literature

Novel therapeutic agents for asthma disclosed in recent patents

Vion begins phase I/II brain tumor trial combining Cloretazine and Temodar

Hollis-Eden files IND for HE-3286 for inflammation

Recent patents report new therapeutic agents for disorders associated with impaired metabolism

Pegnaloxol -- a potential treatment for opioid-induced bowel dysfunction

SA-1-204 effective against extended spectrum beta-lactamases

Snapshots of clinical results in sleep research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...